Edition:
India

Eisai Co Ltd (4523.T)

4523.T on Tokyo Stock Exchange

5,312JPY
18 Sep 2019
Change (% chg)

¥-76 (-1.41%)
Prev Close
¥5,388
Open
¥5,347
Day's High
¥5,419
Day's Low
¥5,284
Volume
1,410,000
Avg. Vol
862,945
52-wk High
¥11,320
52-wk Low
¥5,205

Select another date:

Fri, Sep 13 2019

Biogen scraps two late-stage Alzheimer's trials

Sept 13 Biogen Inc and partner Eisai Co Ltd said on Friday they would abandon two late-stage trials testing their experimental treatment, elenbecestat, for patients with early Alzheimer's disease.

Eisai starts phase 3 trials for second Alzheimer's drug after first's failure

TOKYO Eisai Co Ltd on Friday said it has begun phase 3 clinical trials of Alzheimer's treatment BAN2401, a day after the Japanese drugmaker and U.S. partner Biogen Inc scrapped trials for another Alzheimer's drug, aducanumab.

Eisai starts phase 3 trials for second Alzheimer's drug after first's failure

TOKYO Eisai Co Ltd on Friday said it has begun phase 3 clinical trials of Alzheimer's treatment BAN2401, a day after the Japanese drugmaker and U.S. partner Biogen Inc scrapped trials for another Alzheimer's drug, aducanumab.

Nikkei falls as financials drag; Eisai indicated to dive

TOKYO, March 22 Japan's Nikkei fell in choppy trade on Friday as financial stocks languished, reflecting more cautious U.S. monetary policy, while the drug sector tumbled after Eisai and Biogen said they will end their Alzheimer's drug trials.

Shares of Japan's Eisai swamped with sell orders after ending Alzheimer trials

TOKYO Eisai Co Ltd's shares were untraded on Friday, hit with a glut of sell orders after the Japanese drugmaker and its partner Biogen Inc said they are ending two drug trials of their experimental Alzheimer's disease drug aducanumab.

Biogen, Eisai scrap Alzheimer drug trials

March 21 Biogen Inc and Eisai Co Ltd said on Thursday they will discontinue two late-stage trials testing an experimental treatment for Alzheimer's disease.

Select another date: